Biospecimen Management Consortium

Driving sample excellence in clinical research.

Setting global standards
Streamlining operations & data
Shaping regulatory policy

About the Biospecimen Management Consortium

The BMC is a clinical trial industry partnership dedicated to driving sample excellence in clinical research.

Founded in June 2024, the BMC mission is to raise awareness of the importance and criticality of biospecimen management, develop industry standards and best practices, and advocate for change within the clinical trial ecosystem through standardization, policy, and thought leadership.

Vision

To elevate industry-wide excellence in biospecimen management, raise the bar for data integrity and quality, enable the future of complex clinical research, and protect precious patient samples.

"

This important initiative challenges the status quo of how biospecimens are managed today, in order to ensure the success and accuracy of complex clinical trials that rely so heavily on this data and the timelines associated with it."

Trena Depel
VP Clinical, Regulatory, Quality
Teal Health
Biospecimen Management Consortium Accelerates Growth, Releases Landmark Industry Survey, and Launches Key Initiatives

Our Core Focus

Regulatory & Policy

Identify and influence key regulations and policies impacting proper biospecimen lifecycle management.

Operations

Drive innovation at the intersection of people, process, and technology for more efficient, compliant, and higher quality trials.

Data

Protect sample data integrity throughout the entire biospecimen lifecycle.

Bring your voice to the future of clinical trials

Your experience is invaluable, and your insights could forge the future of biospecimen management. We invite you to use the form below to: share industry best practices you would like to see implemented; suggest where the BMC should focus its efforts; advise on any challenges we should prioritize and address.

Members

Collaborators